A citation-based method for searching scientific literature

Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon. Nat Rev Clin Oncol 2018
Times Cited: 359



Alessio Amatu, Andrea Sartore-Bianchi, Salvatore Siena. ESMO Open 2016
Times Cited: 222




List of shared articles



Times cited

Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions.
Iva Brčić, Theresa Maria Godschachner, Marko Bergovec, Jasminka Igrec, Holger Till, Herwig Lackner, Susanne Scheipl, Karl Kashofer, Thomas Brodowicz, Andreas Leithner,[...]. Mod Pathol 2021
8

NTRK and other recently described kinase fusion positive uterine sarcomas: A review of a group of rare neoplasms.
Sabrina Croce, Isabelle Hostein, W Glenn McCluggage. Genes Chromosomes Cancer 2021
1

Chromosomal imbalances detected in NTRK-rearranged sarcomas by the use of comparative genomic hybridisation.
Ana Cristina Vargas, Nima M Ardakani, Daniel D Wong, Fiona M Maclean, Joseph Kattampallil, Richard Boyle, Leonardo Santos, Anthony J Gill. Histopathology 2021
0

[Diagnosis and therapy of tumors with NTRK gene fusion].
Albrecht Stenzinger, Cornelis M van Tilburg, Ghazaleh Tabatabai, Florian Länger, Norbert Graf, Frank Griesinger, Lukas C Heukamp, Michael Hummel, Thomas Klingebiel, Simone Hettmer,[...]. Pathologe 2021
1


Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer.
Hedvig Elfving, Erika Broström, Lotte N J Moens, Jonas Almlöf, Dijana Cerjan, Gilbert Lauter, Helena Nord, Johanna S M Mattsson, Gustav J Ullenhag, Carina Strell,[...]. Lung Cancer 2021
2

Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials.
Nai-Jung Chiang, Li-Tzong Chen, Yan-Shen Shan, Chun-Nan Yeh, Ming-Huang Chen. Biomolecules 2021
1

Assessment of the toxicity and toxicokinetics of the novel potent tropomyosin receptor kinase (Trk) inhibitor LPM4870108 in rhesus monkeys.
Sijin Duan, Lin Dong, Bingsi Wang, Shujuan Wei, Xiaoyan Gong, Pengfei Yu, Chunmei Li, Yonglin Gao, Liang Ye, Hongbo Wang,[...]. Regul Toxicol Pharmacol 2021
1

Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
Roberto Filippi, Ilaria Depetris, Maria Antonietta Satolli. Expert Opin Pharmacother 2021
0

Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours.
P Garrido, R Hladun, E de Álava, R Álvarez, F Bautista, F López-Ríos, R Colomer, F Rojo. Clin Transl Oncol 2021
0

Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.
Alice Boilève, Loïc Verlingue, Antoine Hollebecque, Valérie Boige, Michel Ducreux, David Malka. Expert Opin Investig Drugs 2021
1

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers.
Tingting Jiang, Guan Wang, Yao Liu, Lu Feng, Meng Wang, Jie Liu, Yi Chen, Liang Ouyang. Acta Pharm Sin B 2021
6


A novel agnostic tumor: NTRKoma.
Ruveyda Ayasun, Deniz Can Guven, Ibrahim Gullu. J Oncol Pharm Pract 2021
0

TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks.
Alessandro Rizzo, Giovanni Brandi. Cancer Treat Res Commun 2021
2

NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects.
Vasiliki Siozopoulou, Evelien Smits, Koen De Winne, Elly Marcq, Patrick Pauwels. Diagnostics (Basel) 2021
0

Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities.
Loredana Lorusso, Virginia Cappagli, Laura Valerio, Carlotta Giani, David Viola, Luciana Puleo, Carla Gambale, Elisa Minaldi, Maria Cristina Campopiano, Antonio Matrone,[...]. Int J Mol Sci 2021
2

NTRK genes and cancer: when arresting the fusion underlies the treatment.
Khalil El Gharib, Hampig R Kourie. Epigenomics 2021
0

Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
Shivaani Kummar, Jordan Berlin, Leo Mascarenhas, Cornelis M van Tilburg, Birgit Geoerger, Ulrik N Lassen, Russell J Schilder, Brian Turpin, Shivani Nanda, Karen Keating,[...]. Curr Probl Cancer 2021
1

TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting.
Lyudmila Bazhenova, Andrew Lokker, Jeremy Snider, Emily Castellanos, Virginia Fisher, Marc Fellous, Shivani Nanda, Jihong Zong, Karen Keating, Xiaolong Jiao. Target Oncol 2021
0

Evolving role of entrectinib in treatment of NTRK-positive tumors.
Neal Chawla, Nam Q Bui, Mahesh Seetharam. Future Oncol 2021
0